Kilitch Drugs (India) Valuation

Q: What is the Fair Price of KILITCH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

KILITCH (₹307.45) is trading above our estimate of [[fair value]] (₹72.75)

Is KILITCH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KILITCH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KILITCH (₹307.45) is trading above our estimate of fair value (₹72.75)

Significantly Below Fair Value: KILITCH is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KILITCH?

Key metric: As KILITCH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for KILITCH. This is calculated by dividing KILITCH's market cap by their current earnings.
What is KILITCH's PE Ratio?
PE Ratio	30x
Earnings	₹164.61m
Market Cap	₹4.97b

KILITCH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	26.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does KILITCH's PE Ratio compare to its peers?

The above table shows the PE ratio for KILITCH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	57.8x
530477 Vikram Thermo (India)	99.9x	n/a	₹5.5b
531739 Gennex Laboratories	25.6x	n/a	₹4.4b
531146 Medicamen Biotech	73.9x	n/a	₹5.7b
541400 ZIM Laboratories	32x	n/a	₹5.1b
KILITCH Kilitch Drugs (India)	30x	n/a	₹5.0b

Price-To-Earnings vs Peers: KILITCH is good value based on its Price-To-Earnings Ratio (30x) compared to the peer average (57.8x).

Price to Earnings Ratio vs Industry

How does KILITCH's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.6x	n/a	US$70.56m
524652 Ind-Swift	2x	n/a	US$13.15m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: KILITCH is good value based on its Price-To-Earnings Ratio (30x) compared to the Indian Pharmaceuticals industry average (31.7x).

Price to Earnings Ratio vs Fair Ratio

What is KILITCH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KILITCH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	30x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate KILITCH's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹294.55

-0.4%

-21.5%

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Granules India

₹135.5b

Manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly.

532482

₹574.50

8.6%

48.3%